To assess the effectiveness of these therapies on pain reduction and quality of life improvement, study authors searched various databases for randomized or quasi-randomized clinical trials that evaluated these outcomes in fibromyalgia patients.
A new case of cutaneous lupus erythematosus or systemic lupus erythematosus could potentially be drug induced.
Early treatment with glucocorticoids may be beneficial for patients hospitalized with COVID-19 who have high levels of inflammation due to the disease.
Colchicine could potentially play a role in the treatment of hospitalized patients with COVID-19.
Prescription fill patterns of medications associated with potential benefits, as well as possible harms, during the COVID-19 pandemic described in new analysis.
The use of immune globulin therapy appears to benefit children who experience acute heart failure caused by coronavirus disease 2019 (COVID-19)-related multisystem inflammatory syndrome, according to the findings of a case series recently published in Circulation.
Recommendations on the management of COVID-19 were recently released by the NIH to help guide clinicians caring for patients with COVID-19.
Allopurinol and febuxostat were found to be associated with a higher risk of hypersensitivity reactions when compared to colchicine, according to the results of a recently published population-based study.
Several treatments were attempted but failed to manage the patient’s conditions, including proton pump inhibitors, topical steroids, a restricted diet, and infliximab (3 doses) for arthritis.
A recently published report presented at the 2019 AIBD Annual Meeting in Orlando, FL, discussed the case of a patient who developed ulcerative colitis (UC) following treatment with Secukinumab for her psoriatic arthritis and highlighted a novel approach for the management of both of her conditions simultaneously.
